DRI Healthcare Trust (DHT-UN) Corporate presentation summary

Business overview and strategy

• Specializes in pharmaceutical royalty monetization, providing capital to advance innovation in life sciences.

• Holds a diversified portfolio of royalties on drugs addressing significant unmet needs, marketed by leading pharma and biotech firms.

• Sourcing deals from inventors, academic institutions, drug developers, and marketers, offering both traditional and synthetic royalty opportunities.

• Competitive advantages include a seasoned team, disciplined capital allocation, proactive sourcing, and strong execution.

• Proprietary database tracks over 7,500 royalties on more than 2,500 drugs, supporting proactive deal origination.

Portfolio and financial performance

• Portfolio consists of 28 royalty streams on 22 products, with no single product exceeding 25% of net book value.

• Therapeutic focus includes ophthalmology (28%), oncology (25%), immunology (19%), and hematology (17%).

• For the twelve months ended March 31, 2026: $205M total income, $166M adjusted EBITDA, and 86% adjusted EBITDA margin.

• Q1 2026 financials: $58.4M total cash receipts (up 6% YoY), $50.6M total income (up 15% YoY), $52.8M adjusted EBITDA (up 2% YoY), $0.68 adjusted cash earnings per unit.

• Strong cash generation enables continued portfolio growth and regular distributions to unitholders.

Transaction highlights and growth opportunities

• Completed 16 royalty transactions since IPO, deploying $1.25B, with significant deals in assets like Ekterly, Casgevy, Omidria, Orserdu, Vonjo, and Xenpozyme.

• Transactions structured for both pre-approval and approved assets, often with milestone-based payments and long-term cash flow potential.

• Pipeline of over $3B in potential opportunities under active evaluation as of March 2026.

• Existing assets have additional indications in clinical development, enhancing future royalty streams.

• Compounding cash flows from reinvestment drive long-term value and acquisition capacity.